Lixte Biotechnology Ownership 2024 | Who Owns Lixte Biotechnology Now?

OverviewFinancials Chart

Institutional Ownership

1.49%

Insider Ownership

20.48%

Retail Ownership

78.03%

Institutional Holders

1.00

Lixte Biotechnology Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ETHOS FINANCIAL GROUP, LLC	-	-	-	-248,084	-100.00%	-	Sep 30, 2023

Lixte Biotechnology's largest institutional shareholder is ETHOS FINANCIAL GROUP, LLC, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ETHOS FINANCIAL GROUP, LLC	-	-	-	-248,084	-100.00%	-	Sep 30, 2023

The largest Lixte Biotechnology shareholder by % of total assets is ETHOS FINANCIAL GROUP, LLC. The company owns 0.00 shares of Lixte Biotechnology (LIXT), representing 0.00% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ETHOS FINANCIAL GROUP, LLC	-	-	-	-248,084	-100.00%	-	Sep 30, 2023

As of Sep 30 2023, Lixte Biotechnology's largest institutional buyer is ETHOS FINANCIAL GROUP, LLC. The company purchased -0.25M stocks of LIXT, valued at -.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ETHOS FINANCIAL GROUP, LLC	-	-	-	-248,084	-100.00%	-	Sep 30, 2023

As of Sep 30 2023, Lixte Biotechnology's biggest institutional seller is ETHOS FINANCIAL GROUP, LLC. The company sold -0.25M shares of LIXT, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ETHOS FINANCIAL GROUP, LLC	-	-	-	-248,084	-100.00%	-	Sep 30, 2023

Lixte Biotechnology's largest sold out institutional shareholder by shares sold is ETHOS FINANCIAL GROUP, LLC, sold -0.25M shares, valued at -, as of undefined.

Lixte Biotechnology Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY COMMONWEALTH TRUST	0.00%	15,395	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	99,991	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	32,745	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	9,998	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	5,209	-5,209	-50.00%	Mar 31, 2024
USAA MUTUAL FUNDS TRUST	0.00%	861	-	-	Jan 31, 2024
iSHARES TRUST	0.00%	12,822	-	-	Mar 31, 2024
EQ ADVISORS TRUST	0.00%	303	-	-	Mar 31, 2024

Lixte Biotechnology's largest mutual fund holder by % of total assets is "FIDELITY COMMONWEALTH TRUST", owning 15.39K shares, compromising 0.00% of its total assets.

Lixte Biotechnology Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Jun, 23	1	-90.91%
31 Mar, 23	11	-26.67%
31 Dec, 22	15	15.38%
30 Sep, 22	13	-7.14%
30 Jun, 22	14	27.27%
31 Mar, 22	11	10.00%
31 Dec, 21	10	11.11%
30 Sep, 21	9	-10.00%
30 Jun, 21	10	42.86%
31 Mar, 21	7	133.33%
31 Dec, 20	3	-

As of 30 Jun 23, 1 institutions are holding Lixte Biotechnology's shares, representing a decrease of -90.91% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Jun, 23	248,084	-54.71%
31 Mar, 23	547,770	-23.02%
31 Dec, 22	711,577	9.67%
30 Sep, 22	648,856	-25.66%
30 Jun, 22	872,865	-27.88%
31 Mar, 22	1,210,240	0.07%
31 Dec, 21	1,209,355	-0.23%
30 Sep, 21	1,212,130	-17.15%
30 Jun, 21	1,463,059	9.57%
31 Mar, 21	1,335,250	492.24%
31 Dec, 20	225,456	-

Lixte Biotechnology (LIXT) has 248.08K shares outstanding as of 30 Jun 23, down -54.71% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Jun, 23	1.49%	1376.60%
31 Mar, 23	0.33%	162.63%
31 Dec, 22	0.45%	296.02%
30 Sep, 22	0.39%	134.26%
30 Jun, 22	0.54%	69.51%
31 Mar, 22	0.88%	113.54%
31 Dec, 21	0.88%	113.04%
30 Sep, 21	0.88%	76.63%
30 Jun, 21	1.07%	98.13%
31 Mar, 21	1.05%	3353.57%
31 Dec, 20	0.18%	-

As of 30 Jun 23, Lixte Biotechnology is held by 1.49% institutional shareholders, representing a 1376.60% growth compared to 31 Mar 23.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Jun, 23	-	-100.00%
31 Mar, 23	5	-16.67%
31 Dec, 22	6	-
30 Sep, 22	6	-14.29%
30 Jun, 22	7	75.00%
31 Mar, 22	4	-33.33%
31 Dec, 21	6	20.00%
30 Sep, 21	5	-16.67%
30 Jun, 21	6	-
31 Mar, 21	6	100.00%
31 Dec, 20	3	-

- institutional shareholders have increased their position in LIXT stock as of 30 Jun 23 compared to 5 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Jun, 23	-	-100.00%
31 Mar, 23	3	-
31 Dec, 22	3	200.00%
30 Sep, 22	1	-75.00%
30 Jun, 22	4	-
31 Mar, 22	4	100.00%
31 Dec, 21	2	100.00%
30 Sep, 21	1	-66.67%
30 Jun, 21	3	-
31 Mar, 21	-	-
31 Dec, 20	-	-

- institutional shareholders have reduced their position in LIXT stock as of 30 Jun 23 compared to 3 in the previous quarter (a -100.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Jun, 23	1	-90.91%	248,084	-54.71%	1.49%	1376.60%	-	-100.00%	-	-100.00%
31 Mar, 23	11	-26.67%	547,770	-23.02%	0.33%	162.63%	5	-16.67%	3	-
31 Dec, 22	15	15.38%	711,577	9.67%	0.45%	296.02%	6	-	3	200.00%
30 Sep, 22	13	-7.14%	648,856	-25.66%	0.39%	134.26%	6	-14.29%	1	-75.00%
30 Jun, 22	14	27.27%	872,865	-27.88%	0.54%	69.51%	7	75.00%	4	-
31 Mar, 22	11	10.00%	1,210,240	0.07%	0.88%	113.54%	4	-33.33%	4	100.00%
31 Dec, 21	10	11.11%	1,209,355	-0.23%	0.88%	113.04%	6	20.00%	2	100.00%
30 Sep, 21	9	-10.00%	1,212,130	-17.15%	0.88%	76.63%	5	-16.67%	1	-66.67%
30 Jun, 21	10	42.86%	1,463,059	9.57%	1.07%	98.13%	6	-	3	-
31 Mar, 21	7	133.33%	1,335,250	492.24%	1.05%	3353.57%	6	100.00%	-	-
31 Dec, 20	3	-	225,456	-	0.18%	-	3	-	-	-

Lixte Biotechnology Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 05, 2023	Bernards Rene	director	-	P-Purchase	Buy	5,527	$2.51	$13.87K	25,000
Oct 05, 2023	Bernards Rene	director	-	P-Purchase	Buy	4,473	$2.29	$10.24K	19,473
Oct 05, 2023	van der Baan Bastiaan Jeroen	director, officer	President and CEO	P-Purchase	Buy	10,000	$2.80	$28.00K	11,000
Oct 04, 2023	Bernards Rene	director	-	P-Purchase	Buy	4,473	$2.29	$10.24K	-
Oct 04, 2023	Bernards Rene	director	-	P-Purchase	Buy	5,527	$2.51	$13.87K	-

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 05, 2023	Bernards Rene	director	-	P-Purchase	Buy	5,527	$2.51	$13.87K	25,000
Oct 05, 2023	Bernards Rene	director	-	P-Purchase	Buy	4,473	$2.29	$10.24K	19,473
Oct 05, 2023	van der Baan Bastiaan Jeroen	director, officer	President and CEO	P-Purchase	Buy	10,000	$2.80	$28.00K	11,000
Oct 04, 2023	Bernards Rene	director	-	P-Purchase	Buy	4,473	$2.29	$10.24K	-
Oct 04, 2023	Bernards Rene	director	-	P-Purchase	Buy	5,527	$2.51	$13.87K	-

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held	Source
Aug 01, 2024	Schellens Johannes Henricus Matthias	officer	Chief Medical Officer		Sell	15,000	$2.39	$35.85K	-

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Aug 01, 2024	Schellens Johannes Henricus Matthias	officer	Chief Medical Officer		Sell	15,000	$2.39	$35.85K	-
Jul 05, 2024	Bernards Rene	director	-	A-Award	Buy	10,000	$2.37	$23.70K	10,000
Jul 05, 2024	Bernards Rene	director	-	A-Award	Buy	4,149	$2.37	$9.83K	4,149
Jul 02, 2024	Yen Yun	director	-	A-Award	Buy	10,000	$2.37	$23.70K	10,000
Jul 02, 2024	Yen Yun	director	-	A-Award	Buy	4,527	$2.37	$10.73K	4,527
Jul 02, 2024	Forman Stephen J.	director	-	A-Award	Buy	10,000	$2.37	$23.70K	10,000
Jul 02, 2024	Forman Stephen J.	director	-	A-Award	Buy	3,018	$2.37	$7.15K	3,018
Jul 02, 2024	Brown Regina	director	-	A-Award	Buy	10,000	$2.37	$23.70K	10,000
Jul 02, 2024	Brown Regina	director	-	A-Award	Buy	4,904	$2.37	$11.62K	4,904
Oct 16, 2023	van der Baan Bastiaan Jeroen	director, officer	President, CEO & Vice Chairman	A-Award	Buy	250,000	$1.95	$487.50K	250,000
Oct 05, 2023	Bernards Rene	director	-	P-Purchase	Buy	5,527	$2.51	$13.87K	25,000
Oct 05, 2023	Bernards Rene	director	-	P-Purchase	Buy	4,473	$2.29	$10.24K	19,473
Oct 05, 2023	van der Baan Bastiaan Jeroen	director, officer	President and CEO	P-Purchase	Buy	10,000	$2.80	$28.00K	11,000
Oct 04, 2023	Bernards Rene	director	-	P-Purchase	Buy	4,473	$2.29	$10.24K	-
Oct 04, 2023	Bernards Rene	director	-	P-Purchase	Buy	5,527	$2.51	$13.87K	-
Sep 27, 2023	van der Baan Bastiaan Jeroen	director, officer	President and CEO	A-Award	Buy	250,000	$1.95	$487.50K	250,000
Sep 27, 2023	van der Baan Bastiaan Jeroen	director, officer	President and CEO	A-Award	Buy	25,000	$7.40	$185.00K	25,000
Sep 27, 2023	van der Baan Bastiaan Jeroen	director, officer	President and CEO	A-Award	Buy	10,000	$5.88	$58.80K	10,000
Jul 07, 2023	van der Baan Bastiaan Jeroen	director	-	A-Award	Buy	25,000	$7.40	$185.00K	25,000
Jul 07, 2023	van der Baan Bastiaan Jeroen	director	-	A-Award	Buy	10,000	$5.88	$58.80K	10,000

The last insider sell of Lixte Biotechnology's stock was made by Schellens Johannes Henricus Matthias on Aug 01 2024, selling 15,000 shares at $2.39 per share (valued at $35.85K). The last insider buy of LIXT was made by Bernards Rene on Oct 05 2023, buying 5,527 shares at $2.51 per share (worth $13.87K).

Lixte Biotechnology Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	6	-	-
Q4 2023	5	-	-
Q3 2023	2	-	-
Q2 2023	5	-	-
Q4 2022	18	-	-
Q2 2022	10	2	500.00%
Q4 2021	-	2	-
Q2 2021	9	-	-
Q1 2021	6	-	-
Q4 2020	16	-	-
Q3 2020	-	2	-
Q4 2018	9	2	450.00%
Q3 2018	-	2	-
Q2 2017	-	1	-
Q1 2017	1	-	-
Q2 2016	1	1	100.00%
Q1 2016	5	-	-
Q3 2015	-	3	-
Q1 2015	2	-	-
Q2 2014	-	2	-

6 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Lixte Biotechnology's insiders, as of Q2 2024.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q2 2024	-	-	-
Q4 2023	5	-	-
Q3 2023	-	-	-
Q2 2023	-	-	-
Q4 2022	14	-	-
Q2 2022	-	-	-
Q4 2021	-	-	-
Q2 2021	-	-	-
Q1 2021	-	-	-
Q4 2020	14	-	-
Q3 2020	-	-	-
Q4 2018	8	-	-
Q3 2018	-	-	-
Q2 2017	-	-	-
Q1 2017	1	-	-
Q2 2016	-	-	-
Q1 2016	4	-	-
Q3 2015	-	-	-
Q1 2015	1	-	-
Q2 2014	-	-	-

As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Lixte Biotechnology's stocks.

Lixte Biotechnology Peer Ownership

Ticker	Company
SRRK	Scholar Rock Holding Corporation
OLMA	Olema Pharmaceuticals, Inc.
ENOB	Renovaro Biosciences Inc.
BDRX	Biodexa Pharmaceuticals Plc
PMVP	PMV Pharmaceuticals, Inc.
KTTA	Pasithea Therapeutics Corp.
QNRX	Quoin Pharmaceuticals, Ltd.
HILS	Tharimmune, Inc.
PASG	Passage Bio, Inc.
VRAX	Virax Biolabs Group Limited
ALLR	Allarity Therapeutics, Inc.
INDP	Indaptus Therapeutics, Inc.
NRBO	NeuroBo Pharmaceuticals, Inc.

LIXT Ownership FAQ

Who Owns Lixte Biotechnology?

Lixte Biotechnology is owned by institutional shareholders (1.49%), insiders (20.48%), and public (78.03%). The largest institutional shareholder of Lixte Biotechnology is ETHOS FINANCIAL GROUP, LLC (0% of total shares) and the top mutual fund owner is FIDELITY COMMONWEALTH TRUST (0.00% of total shares).

Who are the major institutional shareholders of Lixte Biotechnology?

Lixte Biotechnology's major institutional shareholders are ETHOS FINANCIAL GROUP, LLC. The top five shareholders own together 0% of the company's share outstanding.

How many Lixte Biotechnology shareholders are there?

As of Jun 2023, there are 1 institutional shareholders of Lixte Biotechnology.

What percentage of Lixte Biotechnology is owned by ETHOS FINANCIAL GROUP, LLC?

ETHOS FINANCIAL GROUP, LLC owns 0 shares of Lixte Biotechnology, representing 0% of the company's total shares outstanding, valued at $0 (as of Sep 2023).